Orexo has developed from being an R&D stage company to becoming a profitable fully integrated specialty pharmaceutical company with its own commercial business in the US. From a strong operational and financial platform, Orexo is aiming to become a leader in the field of addiction. To achieve this, the commercial business will be broadened through business development, M&A and launch of proprietary pharmaceuticals and digital therapies.
Objectives and strategies 2020 and onwards
Broaden the US commercial platform to leverage scale and expand sales
Maintain Orexo US performance and EBIT contribution
Launch at least one new pharmaceutical product from the pipeline within 2 years and one additional
within the next 3 year
Establish a profitable business within digital therapeutics with the first revenue expected in 2020